Fate Therapeutics, Inc. (FATE) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Fate Therapeutics, Inc. (FATE) Healthcare & Pipeline Overview

Fate Therapeutics, Inc. pioneers off-the-shelf cell therapies for cancer and immune disorders, leveraging its iPSC platform to develop NK- and T-cell immunotherapies. With collaborations including Ono Pharmaceutical and Janssen Biotech, the company aims to deliver scalable, cost-effective treatments in the competitive biotechnology landscape.

What Is the Investment Thesis for FATE?

Fate Therapeutics presents a high-risk, high-reward investment opportunity within the competitive biotechnology sector. The company's iPSC-derived cell therapy platform offers the potential to create scalable and cost-effective cancer immunotherapies, addressing limitations of current autologous approaches. Key value drivers include the clinical progress of its lead candidates, FT516 and FT596, and the expansion of its collaboration agreements. Upcoming data readouts from ongoing clinical trials will be crucial for validating the efficacy and safety of its therapies. However, the company's negative profit margin of -2051.1% and gross margin of -94.1% highlight its reliance on external funding and the inherent risks of drug development. Successful commercialization and market penetration are essential for long-term value creation.

Based on FMP financials and quantitative analysis

FATE Key Highlights

Market capitalization of $272M reflects investor sentiment regarding the potential of Fate Therapeutics' cell therapy platform.

• Negative profit margin of -2051.1% indicates the company's significant investment in research and development and lack of product revenue.
• Gross margin of -94.1% highlights the high cost of goods associated with early-stage clinical development.
• Beta of 2.24 suggests high volatility relative to the broader market, typical for biotechnology companies in the clinical stage.
• Collaboration agreements with Ono Pharmaceutical, Juno Therapeutics, and Janssen Biotech validate the potential of Fate Therapeutics' technology and provide financial support.

Who Are FATE's Competitors?

FATE is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are FATE's Key Strengths?

Proprietary iPSC-derived cell therapy platform.

• Strong intellectual property portfolio.
• Strategic collaborations with major pharmaceutical companies.
• Experienced management team with expertise in cell therapy development.

What Are FATE's Weaknesses?

Clinical-stage company with no approved products and negative profit margins.

• High cash burn rate and reliance on external funding.
• Intense competition in the cell therapy market.
• Risk of clinical trial failures and regulatory setbacks.

What Could Drive FATE Stock Higher?

Data readouts from ongoing clinical trials of FT516 in AML and lymphoma.

• Initiation of clinical trials for FT819 in hematologic malignancies and solid tumors.
• Advancement of strategic collaborations with Ono Pharmaceutical, Juno Therapeutics, and Janssen Biotech.
• Expansion of the company's intellectual property portfolio.
• Development of novel cell therapies targeting new indications.

What Are the Key Risks for FATE?

Financial-distress signal — its Altman Z-Score of -7.98 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-58.9%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures or delays in product approvals.
• Competition from established pharmaceutical companies with greater resources.
• Adverse events or safety concerns associated with cell therapies.
• High cash burn rate and reliance on external funding.
• Changes in reimbursement policies and healthcare regulations.

What Are the Growth Opportunities for FATE?

• Expansion of Clinical Programs: Fate Therapeutics has the opportunity to expand its clinical programs by advancing its pipeline of NK- and T-cell immunotherapies into later-stage clinical trials. Successful clinical data could lead to regulatory approvals and commercialization, driving significant revenue growth.
• Strategic Collaborations: Leveraging strategic collaborations with pharmaceutical companies like Ono Pharmaceutical, Juno Therapeutics, and Janssen Biotech can provide Fate Therapeutics with access to additional funding, expertise, and resources. These collaborations can accelerate the development and commercialization of its cell therapy products, expanding its market reach and revenue potential. The global pharmaceutical market is estimated to be worth over $1 trillion, offering ample opportunities for partnerships.
• Development of Novel Cell Therapies: Fate Therapeutics can capitalize on its iPSC platform to develop novel cell therapies targeting a wider range of cancers and immune disorders. By expanding its product pipeline, the company can diversify its revenue streams and reduce its reliance on its lead candidates. The market for novel therapies is constantly growing, driven by unmet medical needs and advancements in biotechnology.
• Geographic Expansion: Expanding its geographic presence beyond the United States can provide Fate Therapeutics with access to new markets and patient populations. Entering markets in Europe and Asia can significantly increase its revenue potential and establish a global presence. The global healthcare market is expanding rapidly, particularly in emerging economies.
• Advancements in Manufacturing Processes: Improving its manufacturing processes to reduce costs and increase scalability can enhance the competitiveness of Fate Therapeutics' cell therapies. By optimizing its manufacturing capabilities, the company can improve its profit margins and make its therapies more accessible to patients. The biopharmaceutical manufacturing market is constantly evolving, with new technologies and processes emerging regularly.

What Are FATE's Competitive Advantages?

• Proprietary iPSC platform for generating off-the-shelf cell therapies.
• Extensive intellectual property portfolio covering its cell therapy technologies.
• Strategic collaborations with leading pharmaceutical companies.
• Expertise in cell therapy development and manufacturing.

What Does FATE Do?

Fate Therapeutics, Inc., founded in 2007 and headquartered in San Diego, California, is a clinical-stage biopharmaceutical company dedicated to revolutionizing cancer and immune disease treatment through programmed cellular immunotherapies. The company's core technology revolves around induced pluripotent stem cells (iPSCs), which are used to create off-the-shelf natural killer (NK) cell and T-cell therapies. These therapies are designed to be more accessible and scalable than traditional patient-specific cell therapies. Fate Therapeutics' pipeline features a range of NK- and T-cell immuno-oncology programs, including FT516, targeting acute myeloid leukemia (AML), B-cell lymphoma, and advanced solid tumors; FT596, for B-cell lymphoma and chronic lymphocytic leukemia; FT538, aimed at AML and multiple myeloma; FT576 for multiple myeloma; FT819, addressing hematologic malignancies and solid tumors; FT536 for solid tumors; and FT500 for advanced solid tumors. The company has established strategic collaborations with Ono Pharmaceutical Co. Ltd. for the development and commercialization of iPSC-derived CAR T-cell product candidates, Juno Therapeutics, Inc. to identify small molecule modulators, and Janssen Biotech, Inc., further expanding its research and development capabilities and market reach. Fate Therapeutics is focused on advancing its innovative cell therapy programs through clinical trials, with the goal of providing transformative treatments for patients with significant unmet medical needs.

What Products and Services Does FATE Offer?

• Develops programmed cellular immunotherapies for cancer and immune disorders.
• Utilizes induced pluripotent stem cells (iPSCs) to create off-the-shelf NK- and T-cell therapies.
• Conducts clinical trials to evaluate the safety and efficacy of its cell therapy products.
• Collaborates with pharmaceutical companies to advance the development and commercialization of its therapies.
• Focuses on treating hematologic malignancies and solid tumors.
• Aims to provide scalable and cost-effective cell therapy solutions.

How Does FATE Make Money?

• Develops and patents novel cell therapy technologies.
• Conducts preclinical and clinical research to validate the efficacy and safety of its therapies.
• Partners with pharmaceutical companies for co-development and commercialization.
• Out-licenses its technology to other companies for specific applications.
• Generates revenue through collaboration agreements, licensing fees, and potential future product sales.

What Industry Does FATE Operate In?

Fate Therapeutics operates in the rapidly evolving biotechnology industry, specifically within the cell therapy and immuno-oncology sectors. The market for cell therapies is projected to experience substantial growth, driven by increasing demand for personalized medicine and advancements in gene editing technologies. Competition is intense, with companies like Gilead (GILD), Novartis (NVS), and Bristol Myers Squibb (BMY) developing CAR-T cell therapies. Fate Therapeutics differentiates itself through its iPSC-derived off-the-shelf approach, aiming to overcome the limitations of autologous cell therapies in terms of scalability and cost.

Who Are FATE's Key Customers?

• Patients with cancer and immune disorders.
• Hospitals and oncology centers.
• Pharmaceutical companies seeking to expand their cell therapy portfolios.
• Research institutions and academic centers.

Company Profile

Fate Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Diego, US. The company is led by CEO Bahram Valamehr. FATE has traded publicly since 2013.

How Fate Therapeutics, Inc. Is Valued

Fate Therapeutics, Inc. carries a market capitalization of $272M, placing it in the micro-cap category. Relative to its peer group, FATE's quantitative score of 12/100 is below the peer average of 72/100.

Return on equity for Fate Therapeutics, Inc. stands at -58.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -45.6%, showing how much profit it generates from its asset base. Its free cash flow yield is -34.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 5.85 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -40.1%, the inverse of the P/E and a quick read on earnings relative to price.

Fate Therapeutics, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -7.98 places it in the distress zone, a signal of elevated financial risk.

Wall Street analysts project Fate Therapeutics, Inc. revenue of about $5.3M for fiscal 2026, with EPS near $-1.08. The estimate reflects 8 contributing analysts.

Over the past six months, Fate Therapeutics, Inc. insiders filed 29 SEC Form 4 transactions — 9 sales and 20 purchases. On net that is roughly 924K shares acquired (about $1.9M) — insiders putting money in tends to read as conviction.

FATE Financials

FATE Latest News

FATE Analyst Consensus

FATE MoonshotScore

Common Questions About FATE (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources